{"title":"Role of CD9 Sensing, AI, and Exosomes in Cellular Communication of Cancer.","authors":"Neda Baghban, Sai Priyanka Kodam, Mujib Ullah","doi":"10.23937/2469-570X/1410079","DOIUrl":"https://doi.org/10.23937/2469-570X/1410079","url":null,"abstract":"<p><p>Exosomes are small membrane-bound vesicles that are released by various types of cells, including cancer cells, and play a role in intercellular communication. CD9 is a protein that is involved in cell signaling and adhesion. It is found on the surface of various cells, including cancer cells, and has been implicated in the communication between cancer cells and their microenvironment. Exosomes are small membrane-bound vesicles that are released by cells and contain various bioactive molecules, such as proteins, lipids, and nucleic acids. Exosomes have been shown to play a role in intercellular communication, and they have been implicated in the progression of cancer. There is evidence to suggest that CD9 is involved in the packaging and release of exosomes by cancer cells. CD9 has been shown to be important for the formation of tetraspanin-enriched microdomains (TEMs) on the surface of exosomes. These TEMs are thought to be important for the sorting and packaging of specific molecules into exosomes. In summary, CD9 appears to play an important role in the communication between cancer cells and their microenvironment via exosomes. The precise mechanisms by which CD9 mediates this communication are still being investigated, but the involvement of CD9 in exosome packaging and uptake suggests that it may be a promising target for the development of novel cancer therapies. Furthermore, CD9 has been shown to be involved in the uptake of exosomes by recipient cells. For example, studies have shown that CD9-positive exosomes released by cancer cells can be taken up by other cancer cells, leading to the transfer of oncogenic molecules and the promotion of cancer progression.</p>","PeriodicalId":73481,"journal":{"name":"International journal of stem cell research and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9855097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Y. Castillo-Aleman, Y. Ventura-Carmenate, R. A. Rivero-Jiménez, Antonio Bencomo-Hernández
{"title":"Regulatory Prospects of Clinical Trials with Stem Cells in the United Arab Emirates","authors":"Y. Castillo-Aleman, Y. Ventura-Carmenate, R. A. Rivero-Jiménez, Antonio Bencomo-Hernández","doi":"10.23937/2469-570x/1410073","DOIUrl":"https://doi.org/10.23937/2469-570x/1410073","url":null,"abstract":"Health research and clinical trials are driving the development of valuable medical knowledge. Many types of clinical research have been conducted in the United Arab Emirates (UAE) by governmental and private health providers in recent years, and a growing number of publications and UAE-based clinical trials have been registered worldwide. However, there are wide differences between the Emirates regarding the policies governing emerging stem cell therapies. This article aims to discuss the regulatory framework for conducting clinical trials involving stem cell therapies in the UAE. UAE-based clinical trials with stem cells were searched in international registries and national databases. Two health authorities are leading regulatory affairs on stem cells and regenerative medicine: The Department of Health - Abu Dhabi and Dubai Health Authority, while the public databases revealed 7 studies that investigated stem cells in the UAE. We recommend increasing the inter-organizational relationships between health authorities and regulated parties.","PeriodicalId":73481,"journal":{"name":"International journal of stem cell research and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44207221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical Relevance of RNA Editing to Early Detection of Cancer in Human.","authors":"Mujib Ullah, Asma Akbar","doi":"10.23937/2469-570x/1410066","DOIUrl":"https://doi.org/10.23937/2469-570x/1410066","url":null,"abstract":"<p><p>DNA encodes RNA and is responsible for protein production in cells. RNA editing is the process by which genetic information is altered in the RNA molecule. RNA editing in cancer initiation, progression and development has been well documented and play an important role in tumorigenesis. Studying RNA editing and its application to change genetic information after transcription, RNA-editing technology could be an important innovation in cancer and has the potential for more effective precision treatment. Bioengineering integration approach and artificial intelligence could revolutionize the entire field of RNA editing for early detection of cancer.</p>","PeriodicalId":73481,"journal":{"name":"International journal of stem cell research and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38626441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Mesenchymal Stem Cell Based Therapy for Parkinson's Disease","authors":"A. SalemNeveen","doi":"10.23937/2469-570x/1410062","DOIUrl":"https://doi.org/10.23937/2469-570x/1410062","url":null,"abstract":"Parkinson’s disease (PD) is a chronic, progressive, neurodegenerative disease with a multifactorial etiology, the predominant pathology of PD is the loss of dopaminergic cells in the substantia nigra. It is characterized by hallmark signs of bradykinesia, rigidity, tremor, and postural instability. Medical and pharmacological treatments for Parkinson’s disease are limited to the symptomatic relief of patients, and has failed to prevent or slow down the process of neurodegeneration. Cell transplantation is a strategy with great potential for the treatment of Parkinson’s disease, Mesenchymal stem cells are a great therapeutic cell source because they are easy accessible. They have trophic effects for protecting damaged tissues as well as differentiation ability to generate a broad spectrum of cells, including dopamine neurons, which contribute to the replenishment of lost cells in Parkinson’s disease.","PeriodicalId":73481,"journal":{"name":"International journal of stem cell research and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45872052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mousavi Seyed Mohammad Hadi, A. Saeid, S. Masoud, M. Javad
{"title":"Potential of Polycaprolactone Nanofiber Scaffold for Ex Vivo Expansion of Cord Blood-Derived CD34+ Hematopoietic Stem Cells","authors":"Mousavi Seyed Mohammad Hadi, A. Saeid, S. Masoud, M. Javad","doi":"10.23937/2469-570X/1410059","DOIUrl":"https://doi.org/10.23937/2469-570X/1410059","url":null,"abstract":"Background: An efficient and practical ex vivo expansion of cord blood hematopoietic stem cells as an alternative source of HSC transplantation is crucial in understanding the potential of HSC transplantation in treating or supportive therapy in a variety of hematologic and non-hematologic disorders. The aim of this study was an ex vivo expansion of cord blood hematopoietic stem cells in a novel threedimensional polycaprolactone nanofiber scaffold coated with collagen. Methods: After 10-day cultured of cord blood CD34+ cells in 2-Dimensional and 3-Dimensional culture system, the evaluation was performed by qRT-PCR, flow cytometry and clonogenicity. Results: 3-Dimensional Polycaprolactone nano-scaffold coated with collagen provided higher total nucleated cells (50-fold vs. 38-fold) and CD34+ cells (20-fold vs. 2.6-fold) (p < 0.05) and compared to 2-Dimensional cell culture and before expansion had higher expression of homing and self-renewal genes and for VLA-4, hTERT and BMI-1 genes were statically significant (p = 0.0001). The expression of myeloid markers in 3-Dimensional scaffold was significantly higher than the 2-Dimensional culture system (p < 0.05). The total colony in 2-Dimensional culture was lower than 3-Dimensional culture medium (p < 0.05). Conclusion: This study demonstrated the synergistic effect between the three-dimensionality of the scaffold and collagen as an extracellular matrix protein, and the potential of this 3-Dimensional Polycaprolactone nanofiber scaffold coated with collagen for ex vivo expansion of HSCs.","PeriodicalId":73481,"journal":{"name":"International journal of stem cell research and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47588024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Testicular Expression of SCP-3, Gfra, and Sca-1 in Induced Azoospermatic Male Mice Treated with Honey, Bovine Colostrum and Umbilical Cord Blood Derived Mesenchymal Stem Cells","authors":"Hassan Somia, Z. Faten, W. Shimaa","doi":"10.23937/2469-570X/1410060","DOIUrl":"https://doi.org/10.23937/2469-570X/1410060","url":null,"abstract":"","PeriodicalId":73481,"journal":{"name":"International journal of stem cell research and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42774053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Human Umbilical Cord Stem Cells in Chitosan Attenuate Myocardial Injury in Rat Cardiac Infarction","authors":"R. Henning, Abraham Khan, Xiao Wang","doi":"10.23937/2469-570X/1410061","DOIUrl":"https://doi.org/10.23937/2469-570X/1410061","url":null,"abstract":"Background: Myocardial infarction (MI) is the leading cause of cardiovascular deaths and disability in the industrialized world. Although stem cells have been injected into hearts to limit MI damage, < 4% of stem cells remain in the heart for > 1 hour due to myocardial contractility which causes the rapid egress of the stem cells through the cardiac veins and lymphatics. We hypothesized that stem cells in chitosan gels would remain longer in the heart and therefore be more beneficial in MI repair. Methods: 100 rats with MIs were divided into Control, Chitosan Gel, human umbilical cord stem cells (hUCBC), or hUCBC in Gel groups for MI injections. Echocardiograms were done before and at 2, 4, and 8 weeks after injections then random hearts were examined for infarct size and histopathology at each time. Results: Control infarcts averaged 25 ± 1%, 26.5 ± 1% and 27 ± 1% of the ventricular area at 2, 4, and 8 weeks. hUCBC in Gel infarcts were smaller than Control, Gel or hUCBC infarcts and averaged 13 ± 0.9%, 11 ± 0.9% and 11 + 0.9% (P < 0.001 vs. controls). hUCBC in Gel periinfarct thicknesses averaged 889 ± 10 μm at 4 weeks and were greater than other groups (P < 0.05). Arteriole densities in hUCBC in Gels averaged 6.3 ± 0.2/high power field and were greater than other Groups (P < 0.05). LV fractional shortening (FS) averaged 49 ± 1% prior to MI and decreased in Controls to 24 ± 1.1%, 16.8 ± 1.2%, and 19.9 ± 1.1%. hUCBC in Gel FS were greater than other groups and averaged 38 ± 1.0%, 38 ± 1.0%, and 39 ± 1.0 (P < 0.001 vs. controls). hUCBC in Gel LV diastolic diameters were smaller than Gel or hUCBC Groups, averaged 0.68 ± 0.05, 0.65 ± 0.03, and 0.64 ± 0.04 (P < 0.05 vs. controls), and were similar to normals. Conclusion: hUCBC in Chitosan Gel exceed Chitosan or hUCBC in decreasing MI size and LV remodeling and increasing peri-infarct ventricular thickness and neovascularization.","PeriodicalId":73481,"journal":{"name":"International journal of stem cell research and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44438835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G MolchanovPavel, E Moreno-CuevasJorge, Hernández-Torre Martín, Gonzalez-Garza Maria Teresa, Garcia Charles, Hillhouse Edward William, L. Christine, M ZsigmondEva, W. Rick, M. John, Zeng Hong, Kim Jeewon, Yang Jieying, Cuevas Raquel, M BulaiPavel, N PitlikTaras, A DenisovAndrey, N CherenkevichSergey, Molchanova Alla Yu, N GolubevaElena, A StrukovVictor, Boksha Victor
{"title":"Fluorescence-Activated on-Chip Cell Culture Sorting (O3CS): Smart Petri Dish","authors":"G MolchanovPavel, E Moreno-CuevasJorge, Hernández-Torre Martín, Gonzalez-Garza Maria Teresa, Garcia Charles, Hillhouse Edward William, L. Christine, M ZsigmondEva, W. Rick, M. John, Zeng Hong, Kim Jeewon, Yang Jieying, Cuevas Raquel, M BulaiPavel, N PitlikTaras, A DenisovAndrey, N CherenkevichSergey, Molchanova Alla Yu, N GolubevaElena, A StrukovVictor, Boksha Victor","doi":"10.23937/2469-570X/1410055","DOIUrl":"https://doi.org/10.23937/2469-570X/1410055","url":null,"abstract":"On-chip cell sorting is a promising technique for sorting stem cells in culture. On-chip cell sorting allows minimization of lab personnel involvement in cells processing, dramatically reducing the risk of cell culture contamination. We developed a fluorescence-activated On-Chip Cell Culture Sorting (O3CS) system, which combines a biocompatible semiconductor light addressable microarray (chip) and optical setup for chip addressing and cell culture observation. The optical setup has fluorescent and reflected-light microscope capability for visualization and control of cell populations. High-resolution detection of ‘unwanted’ cells with a high-efficient sorter, based on light-induced electroporation is in the core of the O3CS implemented in NeuroSyntek StemOptimizer 6+. We demonstrated capability of the system to perform cell culture fluorescence activated sorting by inducing irreversible single-cell electroporation, validated O3CS sorting efficacy with fluorescent microscopy and flow cytometry, and compared it with the magnetic-activated cell sorting, demonstrating vastly superior performance in selectivity, efficiency, and sorting speed. RESEARCH ARTiCLE","PeriodicalId":73481,"journal":{"name":"International journal of stem cell research and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47136344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Mechanical Stimulation Increases the Proliferation and Differentiation Potential of Human Adipose-Derived Stromal Cells","authors":"Jungwirth Susanne, Bohner Lauren, Spindler Kathrin, Hanisch Marcel, Kleinheinz Johannes, Sielker Sonja","doi":"10.23937/2469-570X/1410056","DOIUrl":"https://doi.org/10.23937/2469-570X/1410056","url":null,"abstract":"Background: Dynamic conditions stimulate the bone remodeling process by improving the nutrients transport and increasing the expression of osteogenic cells. The purpose of this study was to evaluate the effect of mechanical stimulation on the osteogenic differentiation of human adipose-derived stromal cells. Methods: Cells were cultured under static and dynamic conditions in collagen scaffolds for 14 days. The mechanical stimulation was performed using a biaxial rotating bioreactor (5 × rpm and perfusion flow rate of 10 × rpm). Cell viability was analyzed with a living cell count and a MTT assay. Changes in expression of specific stem cell marker, osteogenic marker and endothelial markers were analyzed on gene (RT-qPCR) and protein (IHC) level. Data were statistically analyzed by one-way ANOVA (p = 0.05). Results: Cell viability was higher under dynamic condition and cells migrated deeper in the collagen matrix. Expression of stem cell marker (ANPEP/CD13, CD44, THY1/CD90) was significant higher under dynamic condition. This was also observed for osteogenic markers (collagen 1, osteopontin, osteonectin). Conclusion: The mechanical stimulation increased significantly cell viability and differentiation potential of human adipose-derived stromal cells.","PeriodicalId":73481,"journal":{"name":"International journal of stem cell research and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47936726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fernández-Guinea Sara, Z. Mercedes, G. Estefania, Mucientes Jorge, L. Cristina, Fernández-Mateos Cecilia, V. Jesús
{"title":"Late Intrathecal Cell Therapy Increases Brain Glucose Metabolism and Improves the Long-Term Established Sequelae of Cerebral Hemorrhage","authors":"Fernández-Guinea Sara, Z. Mercedes, G. Estefania, Mucientes Jorge, L. Cristina, Fernández-Mateos Cecilia, V. Jesús","doi":"10.23937/2469-570X/1410058","DOIUrl":"https://doi.org/10.23937/2469-570X/1410058","url":null,"abstract":"Background: The possibility of an increase in brain glucose metabolism after intrathecal administrations of autologous mesenchymal stromal cells (MSCs) has been recently reported, suggesting a role in the treatment of neurological disorders. We describe here the utility of this type of cell therapy in chronic neurological sequelae due to cerebral hemorrhage. Methods: A 49-year-old female suffered from 2009 severe neurological sequelae after spontaneous intracerebral hemorrhage open to ventricle in the left frontoparietal region. Eight years later, she received 3 intrathecal administrations of 100 million autologous MSCs each three months, until a total dose of 300 million. Results: From the first administration of MSCs, the patient reported a clear and progressive improvement that is maintained one year after finishing the cell therapy. The neurological improvement was associated to a progressive increase in global brain glucose metabolism measured by 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET). Conclusions: Late intrathecal administration of cell therapy with autologous MSCs may be a useful strategy to achieve improvement of chronic neurological sequelae due to hemorrhagic stroke.","PeriodicalId":73481,"journal":{"name":"International journal of stem cell research and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42286145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}